Oncoinvent (ONCIN) Investor update summary

Executive summary

• Focused on advancing a phase II trial for Radspherin in peritoneal carcinomatosis and ovarian cancer, with 37 patients recruited and 10 hospitals actively enrolling as of the quarter's end.

• Achieved a new Chinese patent for Radspherin, strengthening IP protection in China.

• Published clinical data in Gynecologic Oncology and presented at ESGO Conference.

• Hired a new CFO, Dr. Ramzi Amri, who brings both medical and strategic expertise.

• RadspherinⓇ is a receptor-independent alpha radiopharmaceutical in clinical development for ovarian and colorectal cancer.

Outlook and guidance

• Current cash reserves of NOK 130 million are expected to fund operations into 2027, supporting ongoing clinical R&D.

• Exploring strategic partnerships, business development, and capital market opportunities to extend financial runway.

• Recruitment momentum is strong, with plans to add more hospitals and optimize patient enrollment using digital tools.

• Clinical R&D expenses are expected to scale with recruitment, but no material changes to operating cash burn are anticipated in the near term.

Segment performance

• Phase II trial in ovarian cancer is ongoing, with FDA Fast Track designation and data readouts expected in 2026–2028.

• Phase I/II-A in colorectal cancer showed promising efficacy and safety, supporting further development.

• Positive final data from Phase 1 trial for ovarian cancer published in a peer-reviewed journal and presented at a major conference.